SCHEMBL481392

SCHEMBL481392

CCCc1c(N)ccc(C(C)=O)c1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.47
PPARD Q03181 2/20 0.47
PPARA Q07869 2/20 0.47
LMNA P02545 2/20 0.47
CYP1A2 P05177 1/20 0.47
MAPT P10636 1/20 0.47
CYP2C9 P11712 1/20 0.47
NFKB1 P19838 1/20 0.47
BLM P54132 1/20 0.47
GRM2 Q14416 1/20 0.47
CYSLTR2 Q9NS75 15/20 0.46
CYSLTR1 Q9Y271 15/20 0.46
MEN1 O00255 1/20 0.43
GLA P06280 1/20 0.43
CYP3A4 P08684 1/20 0.43
ALOX5 P09917 1/20 0.43
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
PTGS1 P23219 1/20 0.43
PTGS2 P35354 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2924329 0.86 MMP2 (0.46) PPARAGRM2KMT2A
SCHEMBL480388 0.82 CYP1A2 (0.50) PPARGPPARDPPARALMNACYP1A2
SCHEMBL30736074 0.82 CYP1A2 (0.50) PPARGPPARDPPARALMNACYP1A2
SCHEMBL6932259 0.81 PPARG (0.48) PPARGPPARDPPARALMNACYP1A2
SCHEMBL13452821 0.81 PPARG (0.48) PPARGPPARDPPARALMNACYP1A2
SCHEMBL481237 0.79 GRM2 (0.50) PPARGPPARDPPARALMNACYP1A2
SCHEMBL8672731 0.79 NOS2 (0.38) CYP1A2MAPTCYP2C9MEN1GLA
SCHEMBL9177662 0.78 CYSLTR2 (0.50) PPARGPPARDPPARALMNACYP1A2
SCHEMBL7041417 0.78 CYP1A2 (0.47) PPARGPPARDPPARALMNACYP1A2
SCHEMBL7968145 0.77 CYSLTR2 (0.49) PPARGPPARDPPARALMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2441762-A1 Potentiators of Glutamate Receptors Eli Lilly and Company (US) 2012-04-18 EP disclosed
EP-1817301-B1 POTENTIATORS OF GLUTAMATE RECEPTORS LILLY CO ELI (US) 2012-02-01 EP disclosed
US-7816523-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2010-10-19 US disclosed
US-7803938-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2010-09-28 US disclosed
US-20090318481-A1 Potentiators Of Glutamate Receptors AICHER THOMAS DANIEL 2009-12-24 US disclosed
US-20090318483-A1 Potentiators Of Glutamate Receptors AICHER THOMAS DANIEL 2009-12-24 US disclosed
US-7598423-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2009-10-06 US disclosed
US-20080139505-A1 Potentiators Of Glutamate Receptors ARRAY BIOPHARMA, INC. 2008-06-12 US disclosed
EP-1817301-A1 POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2007-08-15 EP disclosed
WO-2006057870-A1 POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2006-06-01 WO disclosed
EP-0150966-B1 BENZOPYRAN DERIVATIVES, COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION FISONS plc (GB) 1989-07-12 EP disclosed
US-4698345-A Quinoline derivatives and their use as anti-asthmatic agents FISONS PLC (GB) 1987-10-06 US disclosed
EP-0077090-B1 PROCESS FOR THE PRODUCTION OF QUINOLINE CONTAINING HETEROCYCLES, INTERMEDIATES, AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES FISONS plc (GB) 1986-01-15 EP disclosed
EP-0150966-A2 Benzopyran derivatives, compositions containing them and processes for their preparation FISONS plc (GB) 1985-08-07 EP disclosed
US-4419352-A ANTIALLERGENS; ANTI SECRETORY AGENTS; MUCUS FISONS LIMITED (GB) 1983-12-06 US disclosed
US-4356181-A Anti-allergic mono salt of 6-methylamino-4-oxo-10-propyl-4H-pyrano[3,2-g]-quinoline-2,8-dicarboxylic acid FISONS LIMITED (GB) 1982-10-26 US disclosed
EP-0037187-A1 Salts and aqueous solutions of 6-methylamino-4-oxo-10-propyl-4H-pyrano(3,2-g)-quinoline-2,8-di-carboxylic acid and pharmaceutical compositions containing such salts and solutions FISONS plc (GB) 1981-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139505-A1 Potentiators Of Glutamate Receptors GRM1, GRIN1, GRM2 PPARG 321/4885PPARD 471/4885PPARA 632/4885
US-20090318481-A1 Potentiators Of Glutamate Receptors GRIK1, GRIK2, GRIK4 PPARG 580/4885PPARD 854/4885PPARA 926/4885
US-20090318483-A1 Potentiators Of Glutamate Receptors GRIK1, GRIK2, GRIK4 PPARG 580/4885PPARD 854/4885PPARA 926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.